Cellebrite
- Market cap
- 2.82B
- P/E (TTM)i
- 48.80
- P/Bi
- 5.24
- EPSi
- 0.31
- Div yieldi
- 0.00%
- 52W posi
- 16%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Cellebrite closed at 11.23, down 1.28%. That leaves the company valued at approximately 2.82B, the #2562 most valuable US-listed company we track. Trading at a P/E of 49.43, the stock is 2261% above its own five-year norm of 2.09. Wall Street's 7-analyst consensus lands on Buy, with a price target averaging 16.30 (+45% from here). The shares sit 16% of the way up their 52-week range of 9.58 to 19.98.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 months.
- Recent price momentum is -35.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 3.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 20.7% | Better than 85% |
| Net income CAGR (3Y) | -13.4% | Better than 21% |
| Free cash flow CAGR (3Y) | 140.7% | Better than 97% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 84.2% | Better than 95% |
| Operating margin | 14.0% | Better than 47% |
| Net margin | 16.4% | Better than 66% |
| Return on equity | 19.0% | Better than 65% |
| Return on invested capital | 13.5% | Better than 68% |
Momentum F
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -32.4% | Better than 2% |
| 6-month return | -20.8% | Better than 10% |
| 12-month return (ex latest month) | -39.1% | Better than 5% |
| Distance below 52-week high | 43.9% | Better than 11% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.6x | Better than 54% |
| Debt to assets | 2.4% | Better than 91% |
| Interest coverage | 174.4x | Better than 95% |
| Free cash flow / net income | 204.7% | Better than 84% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 45.5% | Better than 80% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 11.37
- Open
- 11.30
- Day range
- 11.09 - 11.41
- Avg price
- 11.25
- Volume
- 1.85M
- Turnover
- 20.84M
- Turnover ratei
- 1.64%
- Volume ratioi
- 0.80
- Amplitudei
- 2.77%
- 52-week rangei
- 9.58 - 19.98
Valuation
- P/Ei
- 36.21
- P/E (TTM)i
- 48.80
- P/Bi
- 5.24
- EPSi
- 0.31
- Book value / shi
- 2.14
- Net profit
- 77.92M
- Net assets
- 538.12M
Share structure
- Market cap
- 2.82B
- Float capi
- 1.27B
- Shares out
- 251.34M
- Float sharesi
- 112.99M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
43.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.01M net over the window
Short interest
- Shares short
- 9.47M
- % of floati
- 3.77%
- Days to coveri
- 3.49
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Cellebrite (CLBT)?
Cellebrite last traded at 11.23. The quote on this page refreshes every few seconds while US markets are open.
What is Cellebrite's market cap?
About 2.82B.
What is the P/E ratio of Cellebrite?
The trailing twelve-month P/E is 48.80, above its own 5-year average of 2.09 — toward the top of its historical range (90.27% percentile). See the Valuation tab for the full history.
Does Cellebrite pay a dividend?
Cellebrite does not currently pay a regular dividend.
Is Cellebrite a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 16.30, which implies 45.2% upside from the current price. This is not investment advice.
What is Cellebrite's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Cellebrite a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-10-08 04:00:10 · For reference only, not investment advice and not tailored to your situation.